CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression

Yanan Kong, Lu Yang, Weidong Wei, Ning Lyu, Yutian Zou, Guanfeng Gao, Xueqi Ou, Xiaoming Xie, Hailin Tang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: To investigate the role of circRNAs in triple-negative breast cancer (TNBC) and the underlying mechanisms. Materials & methods: We performed circRNA microarrays to explore the expression profiles of TNBC cell lines. Experiments in vitro and in vivo were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and PLK1 in TNBC. Results & conclusion: CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC.

Original languageEnglish (US)
Pages (from-to)1163-1176
Number of pages14
JournalEpigenomics
Volume11
Issue number10
DOIs
StatePublished - Aug 2019

Fingerprint

Triple Negative Breast Neoplasms
Porifera
Neoplasm Metastasis
Neoplasms
Cell Line
Growth

Keywords

  • MiR-296-5p
  • PLK1
  • ceRNAs
  • circPLK1
  • circRNAs
  • miRNAs
  • prognosis
  • therapy
  • triple-negative breast cancer
  • tumor occurrence and metastasis

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. / Kong, Yanan; Yang, Lu; Wei, Weidong; Lyu, Ning; Zou, Yutian; Gao, Guanfeng; Ou, Xueqi; Xie, Xiaoming; Tang, Hailin.

In: Epigenomics, Vol. 11, No. 10, 08.2019, p. 1163-1176.

Research output: Contribution to journalArticle

Kong, Y, Yang, L, Wei, W, Lyu, N, Zou, Y, Gao, G, Ou, X, Xie, X & Tang, H 2019, 'CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression', Epigenomics, vol. 11, no. 10, pp. 1163-1176. https://doi.org/10.2217/epi-2019-0093
Kong, Yanan ; Yang, Lu ; Wei, Weidong ; Lyu, Ning ; Zou, Yutian ; Gao, Guanfeng ; Ou, Xueqi ; Xie, Xiaoming ; Tang, Hailin. / CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression. In: Epigenomics. 2019 ; Vol. 11, No. 10. pp. 1163-1176.
@article{b171ceaf94ca467591f793ff13202bb2,
title = "CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression",
abstract = "Aim: To investigate the role of circRNAs in triple-negative breast cancer (TNBC) and the underlying mechanisms. Materials & methods: We performed circRNA microarrays to explore the expression profiles of TNBC cell lines. Experiments in vitro and in vivo were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and PLK1 in TNBC. Results & conclusion: CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC.",
keywords = "MiR-296-5p, PLK1, ceRNAs, circPLK1, circRNAs, miRNAs, prognosis, therapy, triple-negative breast cancer, tumor occurrence and metastasis",
author = "Yanan Kong and Lu Yang and Weidong Wei and Ning Lyu and Yutian Zou and Guanfeng Gao and Xueqi Ou and Xiaoming Xie and Hailin Tang",
year = "2019",
month = "8",
doi = "10.2217/epi-2019-0093",
language = "English (US)",
volume = "11",
pages = "1163--1176",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression

AU - Kong, Yanan

AU - Yang, Lu

AU - Wei, Weidong

AU - Lyu, Ning

AU - Zou, Yutian

AU - Gao, Guanfeng

AU - Ou, Xueqi

AU - Xie, Xiaoming

AU - Tang, Hailin

PY - 2019/8

Y1 - 2019/8

N2 - Aim: To investigate the role of circRNAs in triple-negative breast cancer (TNBC) and the underlying mechanisms. Materials & methods: We performed circRNA microarrays to explore the expression profiles of TNBC cell lines. Experiments in vitro and in vivo were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and PLK1 in TNBC. Results & conclusion: CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC.

AB - Aim: To investigate the role of circRNAs in triple-negative breast cancer (TNBC) and the underlying mechanisms. Materials & methods: We performed circRNA microarrays to explore the expression profiles of TNBC cell lines. Experiments in vitro and in vivo were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and PLK1 in TNBC. Results & conclusion: CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC.

KW - MiR-296-5p

KW - PLK1

KW - ceRNAs

KW - circPLK1

KW - circRNAs

KW - miRNAs

KW - prognosis

KW - therapy

KW - triple-negative breast cancer

KW - tumor occurrence and metastasis

UR - http://www.scopus.com/inward/record.url?scp=85070766645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070766645&partnerID=8YFLogxK

U2 - 10.2217/epi-2019-0093

DO - 10.2217/epi-2019-0093

M3 - Article

C2 - 31337246

AN - SCOPUS:85070766645

VL - 11

SP - 1163

EP - 1176

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 10

ER -